	US 7,612,075 B2
	Substituted oxoazaheterocyclyl compounds
William R. Ewing, Yardley, Pa. (US); Michael R. Becker, Norristown, Pa. (US); Yong Mi Choi-Sledeski, Belle Mead, N.J. (US); Heinz W. Pauls, Oakville, Calif. (US); Wei He, Audobon, Pa. (US); Stephen M. Condon, Newton, Mass. (US); Roderick S. Davis, West Chester, Pa. (US); Barbara A. Hanney, Pennsburg, Pa. (US); Alfred P. Spada, Carlsbad, Calif. (US); Christopher J. Burns, Malvern, Pa. (US); John Z. Jiang, Collegeville, Pa. (US); Michael R. Myers, Fishers, Ind. (US); Wan F. Lau, Groton, Conn. (US); Aiwen Li, Audubon, Pa. (US); Gregory B. Poli, Perkasie, Pa. (US); Mark A. Bobko, Exton, Pa. (US); Robert L. Morris, Wayne, Pa. (US); Joseph M. Karpinski, Douglassville, Pa. (US); Timothy F. Gallagher, Harleysville, Pa. (US); Kent W. Neuenschwander, Schwenksville, Pa. (US); Robert D. Groneberg, Boulder, Colo. (US); and Jean-Francois Sabuco, Paris (France)
Assigned to Aventis Pharmaceuticals Inc., Bridgewater, N.J. (US)
Filed on Jul. 25, 2003, as Appl. No. 10/628,093.
Application 10/628093 is a continuation of application No. 09/363196, filed on Jul. 28, 1999, abandoned.
Application 09/363196 is a continuation in part of application No. PCT/US99/01682, filed on Jan. 27, 1999.
Claims priority of provisional application 60/072707, filed on Jan. 27, 1998.
Prior Publication US 2004/0102450 A1, May 27, 2004
Int. Cl. A61K 31/497 (2006.01); C07D 401/06 (2006.01)

U.S. Cl. 514—252.13 [544/362]

15 Claims

1. A compound of formula

or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof

wherein

G₁is L₁-Cy₁;

G₂is L₂-Cy₂;

Cy₁and Cy₂are independently selected from optionally substituted heteroaryl, optionally substituted fused arylheterocyclyl, optionally substituted fused arylheterocyclenyl, optionally substituted fused heteroarylcycloalkyl, optionally substituted fused heteroarylcycloalkenyl, optionally substituted fused heteroarylheterocyclyl and optionally substituted fused heteroarylheterocyclenyl;

L₁is —S(O)₂—;

L₂is C_(1-4)alkylene;

A is N;

R₁, R_1a, R₂, R_2a, R₄and R_4aare independently selected from hydrogen, carboxy, alkoxycarbonyl, Y₁Y₂NCO, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl and optionally substituted heteroaralkyl;

R₃and R_3ataken together form O;

m is 1;

n is 1; and

Y₁and Y₂are independently hydrogen, optionally substituted alkyl, optionally substituted aryl, optionally substituted aralkyl or optionally substituted heteroaralkyl, or Y₁and Y₂taken together with the N through which Y₁and Y₂are linked form a monocyclic heterocyclyl.